Rationale: The production of unconditioned defensive behaviors has been related to the amygdala, a key component of the encephalic aversion system. Microinjection of the neuropeptide substance P (SP) in the amygdala elicits defensive behaviors via the activation of type 1 neurokinin (NK-1) receptors. However, no studies have investigated whether intra-amygdala SP/NK-1 mechanisms can elicit other types of defensive responses, such as antinociception and ultrasonic vocalizations (USVs). Methods: The present study investigated the effects of SP-induced activation of the neurokininergic system in three main nuclei of the amygdala-basolateral (BLA), central (CeA), and medial (MeA) nuclei-in rats that were subjected to the elevated plus maze (EPM), tail-flick test, and USV recording. The effects of SP in these amygdaloid nuclei were challenged with combined injections of the NK-1 receptor antagonist spantide. Results: The present study showed that SP injections in the CeA and MeA but not BLA exerted anxiogenic-like effects. In contrast to the CeA, the anxiogenic-like effects of SP in the MeA were not dependent on NK-1 mechanisms. In the tail-flick test, SP microinjections produced antinociceptive effects only in the MeA through NK-1 receptor activation. No USV emissions were detected after the SP microinjections. Conclusions: The present study showed that NK-1 receptors in the CeA and MeA but not BLA are involved in defensive reactions to conditions of fear. The present results may provide a better understanding of the neurochemical mediation of fear states.
Introduction
The organization and production of unconditioned defensive behaviors have been related to the encephalic aversion system, which consists of the amygdala, medial hypothalamus, dorsal periaqueductal gray (dPAG), and superior and inferior colliculi Canteras, 2002; Graeff, 1994) . The amygdala nuclei act as a functional link in the neurocircuitry that is responsible for integrating aversive states in the central nervous system. Several lines of evidence have demonstrated that the basolateral nucleus of the amygdala (BLA) acts as a filter for aversive stimuli to higher structures, whereas the central (CeA) and medial (MeA) nuclei of the amygdala constitute the outputs for autonomic and somatic components of defensive reactions via major projections to the hypothalamus and brainstem (Campeau and Davis, 1995; Canteras et al., 1995; Rizvi et al., 1991; Sah et al., 2003) .
The CeA and MeA are considered key components of pain perception, assigning emotional value to specific sensorial information (Neugebauer et al., 2004) . Previous studies have shown that the CeA acts as a relay structure where nociceptive information from the spinal cord and brainstem can be properly modulated for the expression of precise behavioral and autonomic responses, such as spinal reflexes, vocalizations, and analgesia, in response to specific aversive stimuli (Burstein and Potrebic, 1993; Gauriau and Bernard, 2002; Helmstetter, 1992; Neugebauer et al., 2009; Pare et al., 2004; Rhudy and Meagher, 2000; Wang et al., 1999) . Antinociception has been considered to be part of defensive reactions, and evaluating nociceptive reactivity in http://dx.doi.org/10. 1016 /j.pnpbp.2017 .03.026 Received 10 October 2016 Accepted 8 March 2017 animals that receive injections of neurokinin-1 (NK-1) agents in these amygdaloid nuclei would be interesting (for review, see Brandão et al., 1999; Castilho et al., 2002) .
Electrical stimulation of the amygdala elicits negative emotional reactions, accompanied by aversive vocalizations (Jürgens et al., 1967; Jürgens, 1982) . Likewise, high anxiety states in rats induce the production of ultrasonic vocalizations (USVs) at specific frequencies (~22 kHz), demonstrating that these vocalizations play an important role in intra-species communication (Litvin et al., 2007; Wohr and Schwarting, 2009) . In rats, the playback of 22 kHz USVs alters neuronal firing patterns in the amygdala (Allen et al., 2007; Beckett et al., 1997; Parsana et al., 2012) and Fos expression in the BLA (Sadananda et al., 2008) . Corroborating these data, bilateral inactivation of the CeA blocked the production of aversive vocalizations and freezing behavior (Calvino et al., 1982; Choi and Brown, 2003; Werka, 1997) .
Several neurotransmitters are involved in the chemical modulation of information flow in the amygdala (LeDoux, 1993 (LeDoux, , 2000 . The neuropeptide substance P (SP), which is a neurokinin (NK) that is largely found in brain structures, including the amygdala, is involved in regulating such behavioral processes as fear and anxiety (Bassi et al., 2014; Ebner et al., 2004) . Three types of NK receptors have been identified: NK-1, NK-2, and NK-3. Substance P has high affinity for NK-1 receptors (Quartara and Maggi, 1998; Boyce et al., 2001; Mantyh, 2002) . Previous studies have demonstrated the participation of NK-1 receptors in the amygdala in the production of defensive behaviors (Bassi et al., 2014; Boyce et al., 2001; Smith et al., 1999) . Substance P injections in the CeA and MeA but not BLA elicited anxiogenic-like behavior in the elevated plus maze (Bassi et al., 2014; Carvalho et al., 2013; Ebner et al., 2004) .
These findings led us to investigate whether the activation of neurokininergic (specifically NK-1) mechanisms in the BLA, CeA, and MeA are associated with fear states, analgesia, and USVs. We also microinjected the NK-1 receptor antagonist spantide in these structures prior to administering SP. Two doses of SP (10 and 100 pmol/0.2 μl) were used in a previous study from our laboratory, in which an anxiogenic effect was observed when it was injected in the CeA, whereas no effect was observed when SP was injected in the BLA (Carvalho et al., 2013) . The present study compared the behavioral effects of administering the higher effective dose of SP (100 pmol/ 0.2 μl) in the MeA, CeA, and BLA and challenged these effects by administering the NK-1 antagonist spantide II. Spantide was used because it has been used in several studies in our laboratory over the past decade (Bassi et al., 2007b (Bassi et al., , 2009 Brenes et al., 2012; Carvalho et al., 2013 Carvalho et al., , 2015 . Strong immunoreactivity of NK-1 receptors is found in the MeA in rats, with sparse immunoreactivity in the BLA and low levels in the CeA (Smith et al., 1999; Ribeiro-da-Silva and Hökfelt, 2000) , justifying the use of spantide II as a suitable tool for assessing NK-1 activity because it possesses much stronger antagonist activity for NK-1 receptors than for NK-2 and NK-3 receptors (Janecka et al., 2005; Maggi et al., 1991) .
Materials and methods

Animals
Two hundred three male Wistar rats (150-180 g) were obtained from the breeding facility of the University of São Paulo at Ribeirão Preto. The animals were housed in a temperature-controlled (22 ± 1°C) room and maintained on a 12 h/12 h light/dark cycle, with lights on at 7:00 AM. The rats were housed in groups of five per cage (40 cm × 33 cm × 18 cm) and given free access to food and water. The experiments were performed in accordance with the Brazilian Society of Neuroscience and Behavior Guidelines for the Care and Use of Laboratory Animals. The procedures were approved by the Committee on Animal Research and Ethics (CEUA) of the University of Sao Paulo (no. 09.1.84.54.7).
Surgery
The animals were anesthetized with a mixture of ketamine/xylazine (50 mg/kg and 10 mg/kg, respectively, i.p.) and placed in a stereotaxic frame (David Kopf, Tujunga, CA, USA) with the upper incisor bar set 3.3 mm below the interaural line. A unilateral stainless steel guide cannula (12 mm, 24 gauge) aimed at the right CeA, MeA, or BLA was implanted in each animal. The right amygdala was chosen because the right hemisphere specializes in emotional behavior, particularly negative affect, compared with the left hemisphere (Adamec et al., 1998; Carvalho et al., 2013; Michelgard et al., 2007) Paxinos and Watson, 2005) . The cannulae were fixed to the skull using dental cement and two stainless-steel screws. The rats subsequently received an intramuscular injection of penicillin G benzathine (Pentabiotic, 600,000 IU, 0.2 ml; Fort Dodge, Campinas, SP, Brazil) and a subcutaneous injection of the antiinflammatory and analgesic drug Banamine (flunixin meglumine, 1.25 mg/kg; ScheringPlough, São Paulo, SP, Brazil).
Drugs
Substance P and spantide, both purchased from Sigma (St. Louis, MO, USA), were diluted in phosphate-buffered saline (pH 7.4) shortly before use at doses of 35 pmol/0.2 μl and 100 pmol/0.2 μl, respectively (Bassi et al., 2007a (Bassi et al., , 2014 Carvalho et al., 2013; De Araújo et al., 1999 . The rats were randomly allocated to four groups: (1) saline + saline, (2) SP + saline, (3) spantide + saline, and (4) spantide + SP. Spantide (10 pmol) was also used based on studies that reported its higher efficacy than the higher dose of 100 pmol in reducing fearrelated USVs after brief maternal separation in rats (Schott and Zimmerberg, 2014) and reversing hippocampal SP-induced excitability (Liu et al., 1999) .
Microinjection procedure
Glass micropipettes were used for the microinjections based on previous studies from our laboratory (Santos et al., 2003; Nobre and Brandão, 2004) . The animals were gently wrapped in a cloth and held by the experimenter for insertion of the micropipettes into the guide cannulae. The micropipettes consisted of a fused silica capillary (outer diameter, 150 μm; inner diameter, 75 μm; Cluzeau Info Lab., Marseille, France). To prevent the cannulae from breaking, the capillary was fixed in a device that consisted of 0.60 × 25 mm and 1.00 × 25 mm needles (Becton-Dickinson, Franklin Lakes, NJ, USA). The fused silica capillary protruded 1.0 mm beyond the end of the guide cannula in order to reach the CeA, MeA, or BLA. The micropipette was linked to a 5 μl Hamilton syringe by polyethylene-10 tubing (Becton-Dickinson, Franklin Lakes, NJ, USA) that was connected to a microinfusion apparatus (Harvard Apparatus, South Natick, MA, USA). A total volume of 0.2 μl was injected over 60 s. The displacement of an air bubble inside the polyethylene tubing that connected the syringe needle to the glass needle was used to monitor the microinjections. Following the end of the injections, the microinjection pipettes were left in place for an additional 60 s to maximize diffusion of the drug away from the cannula tip.
Elevated plus maze
The elevated plus maze consisted of two open arms (50 cm × 10 cm) that crossed at right angles with two closed arms of the same size. The closed arms were enclosed by 50 cm high walls, except for the central part where the arms crossed. The entire apparatus was elevated 50 cm above the floor. To prevent the rats from falling, a rim of Plexiglas (0.5 cm high) surrounded the perimeter of the open arms (Pellow et al., 1985) . Luminosity from a fluorescent light at the level of the open arms was 20 lx. The experimental sessions were recorded by a video camera that interfaced with a monitor and video cassette recorder in an adjacent room.
Spantide was microinjected 5 min prior to the SP microinjection in the CeA, MeA, and BLA. Five minutes after the last microinjection, the rats were individually placed in the center of the elevated plus maze, facing a closed arm, and allowed to freely explore the apparatus for 5 min. Before the next rat was tested, the maze was cleaned with a 20% ethanol solution. An observer who was trained to measure elevated plus maze parameters subsequently scored the videotapes using ethological analysis software (Observer) developed by Noldus (Netherlands). We measured the number of entries into both arms and the time spent on different parts of the maze. An arm entry or exit was defined as all four paws entering or exiting an arm, respectively. These data were used to calculate the percentage of open arm entries and percentage of time spent in the open arms. The following risk-assessment behaviors were also analyzed: stretched-attend posture (when the animal stretched to its full length with the forepaws, keeping the hind paws in the same place and turning its back to the anterior position), flat-back approach (locomotion when the animal stretched to its full length and cautiously moved forward), head dipping (dipping the head below the level of the maze floor), and end-arm exploration (the number of times the rat reached the end of an open arm; Anseloni and Brandão, 1997) . Experimental sessions were conducted between 12:00 PM and 6:00 PM.
Tail-flick test
Twenty-four hours after exposing the rats to the elevated plus maze, the animals were placed in a restraint tube from which their tails protruded. Radiant heat was focused on the lower third of the tail of the animal (Ugo Basile, Varese, Italy). Movement of the tail activated a photocell, turning off both the light and a reaction timer. The light intensity was adjusted to achieve baseline latencies of 2.5 and 3.5 s. A maximum latency of 6 s (i.e., the cutoff) was established to minimize tail damage. The baseline trial consisted of determining the average of three individual tests, separated by a 5-min interval, before the microinjections were performed (D'Amour and Smith, 1941) .
Spantide was microinjected 5 min before the SP microinjection in the CeA, MeA, and BLA. Five minutes after the last microinjection, six additional tail-flick latencies were recorded at 5-min intervals. This procedure has been used successfully in our laboratory (Bassi et al., 2007a (Bassi et al., , 2009 ).
Recording of ultrasonic vocalizations
This experiment was conducted to assess whether the treatments induced USVs similarly to SP when it was injected in other structures of the brain aversion system, such as the dPAG (Bassi et al., 2007a (Bassi et al., , 2007b . The apparatus that was used to record and analyze USVs consisted of a testing box (25 cm × 15 cm × 12 cm) that consisted of steel bars that were spaced approximately 12 mm apart. The experimental chamber was situated inside a larger, padded, echo-free (soundattenuated), ventilated box (60 cm × 40 cm × 45 cm) with a 28 W red light bulb that was located at the top of the chamber. For recording and analyzing USVs, an ultrasound microphone (Emkay FG-3629; Avisoft Bioacoustics, Berlin, Germany) that is sensitive to frequencies of 1-100 kHz with a flat frequency response was used. The microphone was connected via an Avisoft UltraSoundGate 116 USB audio device (Avisoft Bioacoustics) to a computer, where acoustic data were displayed in real time by Avisoft Recorder 2.7 software (Avisoft Bioacoustics) and recorded at a sampling rate of 214,285 Hz in 16-bit format. For acoustical analysis, the recordings were transferred to SASLab Pro 4.38 software (Avisoft Bioacoustics), and fast-Fourier transformation (FFT) was performed (512 FFT-length, 100% frame, Hamming window, 75% time window overlap). Spectrograms were produced at a frequency resolution of 488 Hz and a time resolution of 0.512 ms. Call detection was provided by an automatic threshold-based algorithm (threshold, −10 dB; start/end threshold, − 20 dB) and a hold-time mechanism (hold time, 20 ms). A lower cut-off frequency of 1 kHz was used for the analysis of the USV parameters. Various parameters that were derived from the average spectrum of the entire element were determined automatically. The number of calls that were emitted at each frequency served as the statistical unit for each subject. Vocalizations that were recorded at frequencies below 20 kHz were operationally defined as "audible" vocalizations, although this term refers to human capacities.
Spantide was microinjected 5 min before the SP microinjections in the CeA, MeA, and BLA in independent groups of animals. Immediately after the microinjections, the rats were individually placed in the experimental chamber for 15 min. During each test session, the microphone was placed through a hole in the middle of the roof of the chamber, 40 cm above the floor, to record the entire spectrum of USVs. A video camera that was linked to a television set was used to monitor all behavior during the recording period. The USV emissions that were obtained in this experiment were stored on a hard disk and subsequently transferred to tables in Microsoft Excel (Redmond, WA, USA) for off-line analysis. The USV emissions were recorded at 20-24 kHz (aversion-related USVs).
Experimental design
For each amygdaloid nucleus, the same animals were used for the elevated plus maze and tail-flick test. The animals were randomly selected for the elevated plus maze or tail-flick test. Twenty-four hours after the end of the first test, the animals underwent the second test. Tail-flick latencies have been previously shown to not significantly change in rats that are previously subjected to the elevated plus maze (Albrechet-Souza et al., 2005) . Independent groups of animals that were implanted with cannulae in the BLA, CeA, and MeA were used for the USV emission test.
Statistical analysis
The data are expressed as mean ± SEM. The data that were obtained from the elevated plus maze and USV test were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test when significant overall F values were obtained in the ANOVA. The tail-flick latencies were analyzed by two-way repeated-measures ANOVA, with treatment as the independent factor and trial as the repeated measure, followed by Bonferroni's post hoc test. In all of the analyses, values of p < 0.05 were considered statistically significant.
Histology
Upon completion of the experiments, the animals were deeply anesthetized with ketamine/xylazine (50 and 10 mg/kg, respectively, i.p.) and intracardially perfused with 0.9% buffered saline followed by 4% buffered formalin solution. Three hours later, the brains were immersed in a 30% sucrose solution. Forty-eight hours later, the brains were frozen, and 60-μm brain sections were cut using a cryostat (Leica, Wetzlar, Germany) to determine the sites of the microinjections according to a rat brain atlas (Paxinos and Watson, 2005) .
Results
The histological examinations indicated that the microinjection sites were located within the CeA, MeA, and BLA (Fig. 1) . The number of sites that are shown in Fig. 1 is less than the actual number of animals used because of several overlapping sites. Thirty-two animals had misplaced cannulae, and six animals were excluded because of obstruction of the cannulae.
Experiment 1: elevated plus maze
In the BLA group, the one-way ANOVA revealed no significant effects on the frequency of entries into and time spent on the open arms (F 3,23 = 0.69 and 0.60, p = 0.71 and 0.60, respectively) and number of entries into the closed arms (F 3,23 = 0.60, p = 0.61; Fig. 2A-C) . For the complementary ethological analysis, the one-way ANOVA did not reveal any significant effects on stretched-attend posture (F 3,23 = 0.20, p = 0.89), flat-back approach (F 3,23 = 0.23, p = 0.86), head dipping (F 3,23 = 1.86, p = 0.16), and end-arm exploration (F 3,23 = 0.55, p = 0.71; Fig. 2D-G, respectively) . These results indicate that NK-1 receptors in the BLA are not involved in the modulation of anxiety-like states. Fig. 3 shows the effects of the combined microinjections on the behavioral parameters in the elevated plus maze in the CeA group. The one-way ANOVA revealed significant effects on the frequency of entries into and time spent on the open arms (F 3,22 = 14.42 and 9.53, both p < 0.001, respectively; Fig. 3B, C) , stretched-attend posture (F 3,22 = 4.87, p = 0.009), flat-back approach (F 3,22 = 11.13, p < 0.001), head dipping (F 3,22 = 5.68, p = 0.004), and end-arm exploration (F 3,22 = 20.56, p < 0.001; Fig. 3D-G, respectively) . The post hoc analysis revealed that the saline + SP group (but not the spantide + saline and spantide + SP groups) exhibited decreases in the frequency of entries into and time spent on the open arms, decreases in the number of head dippings and end-arm exploration, and increases in the number of stretched-attend posture and flat-back approach. These results indicate that intra-CeA microinjections of spantide blocked the anxiogenic-like effects of intra-CeA injections of SP in the elevated plus maze.
For the MeA, the one-way ANOVA revealed significant effects on the frequency of entries into and time spent on the open arms (F 3,26 = 25.77 and 17.25, both p < 0.001, respectively; Fig. 4B, C) , stretched-attend posture (F 3,26 = 8.94, p = 0.003), flat-back approach (F 3,26 = 12.19, p < 0.001), head dipping (F 3,26 = 17.81, p < 0.001), and end-arm exploration (F 3,26 = 18.79, p < 0.001; Fig. 4D -G, respectively). The post hoc analysis revealed similar effects for the CeA, in which the saline + SP group exhibited decreases in the frequency of entries into and time spent on the open arms and decreases in the number of stretched-attend posture, head dipping, end-arm exploration, and flat-back approach. However, the microinjection of spantide prior to SP in the spantide + SP group did not block the anxiogenic-like effects of SP. These results indicate that intra-MeA pretreatment with spantide did not reduce the anxiogenic-like effects of intra-MeA SP in the elevated plus maze. The spantide + saline group did not exhibit any behavioral differences from the control (saline + saline) group.
Experiment 2: tail-flick test
Tail-flick latencies (mean ± SEM) were measured before spantide administration (−10, − 5, and 0 min) and for 30 min (divided into 5-min intervals) after the SP microinjections in the BLA, CeA, and MeA. For the BLA (Fig. 2H) , no significant differences were found among groups during the three baseline tail-flick latency assessments. The two- 
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Progress in Neuropsychopharmacology & Biological Psychiatry 77 (2017) 146-154 way repeated-measures ANOVA revealed significant effects of only time (F 9,207 = 2.59, p = 0.007), with no effect of treatment (F 3,23 = 1.80, p = 0.17) and no treatment × time interaction (F 27,207 = 1.20, p = 0.23). These results indicate that NK-1 receptors in the BLA are not involved in modulating nociception. For the CeA (Fig. 3H) , the two-way repeated-measures ANOVA revealed no significant effects of treatment (F 3,22 = 0.37, p = 0.77) or time (F 9,207 = 0.62, p = 0.77) and no treatment × time interaction (F 27,207 = 0.86, p = 0.66). These results indicate that, similar to the BLA, NK-1 receptors in the CeA are not involved in modulating nociception.
For the MeA (Fig. 4H) , the two-way repeated-measures ANOVA revealed significant effects of treatment (F 3,26 = 41.21, p < 0.001) and time (F 9,234 = 18.02, p < 0.001) and a significant treatment × -time interaction (F 27,234 = 10.94, p < 0.001). Post hoc comparisons indicated that these differences were attributable to the saline + SP group at 0-15 min and spantide + SP group at 0 min. Intra-MeA pretreatment with spantide blocked the analgesic effects of SP, and the spantide + saline group did not exhibit any analgesic/hyperalgesic effects compared with the control (saline + saline) group, indicating that NK-1 receptors in the MeA are not tonically activated.
Experiment 3: ultrasonic vocalizations
Rats that received microinjections of saline + saline, saline + SP, spantide + saline, and spantide + SP in the BLA, CeA, and MeA were subjected to the USV emission test for 15 min after the microinjections. Ultrasonic vocalizations were recorded in the range of 20-24 kHz (aversion-related USVs). The one-way ANOVA revealed no significant differences between the combined microinjections (BLA: F 3,17 = 1.28, p = 0.29; CeA: F 3,20 = 1.55, p = 0.21; MeA: F 3,25 = 2.08, p = 0.11; data not shown). Rats that received microinjections of 10 pmol spantide in the MeA (n = 8) did not emit any 20-24 kHz vocalizations (data not shown). These results indicate that spantide-and SP-treated animals did not emit USVs in the range of 20-24 kHz.
Discussion
Substance P has been implicated in the mediation of anxiety-like behavior in many regions of the brain aversive system, such as the amygdala, medial hypothalamus, and dPAG (Aguiar and Brandão, 1994; Bassi et al., 2007a Bassi et al., , 2014 De Araújo et al., 1999; Shaikh et al., 1993) . Several studies have reported the involvement of NK-1 receptors FAB, flat-back approach; HD, head dipping; EAE, end-arm exploration.
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Progress in Neuropsychopharmacology & Biological Psychiatry 77 (2017) 146-154 in the production of anxiogenic-like behavior in rodents (Bassi et al., 2007a (Bassi et al., , 2014 Carvalho et al., 2013 Carvalho et al., , 2015 Smith et al., 1999; Boyce et al., 2001) . Nonetheless, none of these studies correlated the behavioral effects of intra-amygdala microinjections of SP with the modulation of pain and emission of USVs. The present data showed that SP microinjections in the CeA and MeA but not BLA induced aversive effects in the elevated plus maze, which is consistent with previous studies (Bassi et al., 2007a (Bassi et al., , 2014 Carvalho et al., 2013) . These results indicate that SP in the BLA is not a mediator of the aversiveness associated with the open space and height of the elevated plus maze in rats (i.e., innate fear), in contrast to the CeA and MeA (Carvalho et al., 2013; Pellow et al., 1985) . In the BLA, SP participates in the expression of conditioned behaviors (Zhao et al., 2009 ). The present data indicate that NK-1 receptors in the BLA are not involved in the production of fear-related behaviors. In contrast to the BLA, microinjections of SP in the CeA elicited anxiety-like behavior through the activation of NK-1 receptors, corroborating previous studies (Ebner et al., 2004; Smith et al., 1999) . Although the CeA contains NK-1 receptors (Saffroy et al., 1988 (Saffroy et al., , 2003 and is involved in the expression of pain-related behaviors (Gauriau and Bernard, 2002; Hitchcock and Davis, 1987; LeDoux, 2000) , SP microinjections in the CeA did not alter nociceptive thresholds. Substance P in the CeA elicits anxiety-like states via NK-1 receptor activation, but SP is not involved in pain-related behavior in this nucleus.
Similar to the CeA, SP microinjections in the MeA produced anxietylike behavior, corroborating previous studies (Bassi et al., 2014; Shaikh et al., 1993) . However, in contrast to the CeA, spantide did not block the anxiety-like state that was produced by SP microinjections in the MeA. This finding could be attributable to the activation of other neurokininergic receptors. For example, systemic administration of a NK-3 receptor agonist increased Fos protein expression in the MeA (Yip and Chahl, 1997) , and systemic NK-3 antagonist administration was shown to have anxiolytic-like effects (Ding et al., 1996; Salomé et al., 2006) . In fact, the MeA exhibits NK-3 receptor immunoreactivity (Ding et al., 1996) . In contrast to the BLA and CeA, microinjections of SP in the MeA produced long-lasting analgesia for up to 20 min. This analgesic effect was blocked by spantide. The anxiogenic-like effects of SP administration in the MeA may depend on other neurokininergic receptors and not NK-1. However, the analgesic effects of SP microinjections in the MeA depended on NK-1 receptor activation.
The CeA and MeA are the main outputs for the autonomic and somatic components of emotional reactions via their projections to the The arrow indicates the time at which the microinjections began. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control group (Sal + Sal). Sal + Sal (n = 7), Sal + SP (n = 7), Span + Sal (n = 6), Span + SP (n = 6). SAP, stretch-attend posture; FAB, flat-back approach; HD, head dipping; EAE, end-arm exploration.
G.S. Bassi et al. Progress in Neuropsychopharmacology & Biological Psychiatry 77 (2017) 146-154 hypothalamus and brainstem (Canteras et al., 1995; Sah et al., 2003) . Much evidence has shown that defensive behaviors are mediated by a mechanism that involves the release of SP into the medial hypothalamus via fibers that originate, to a large extent, from the MeA (Shaikh and Siegel, 1994; Han et al., 2007) . Antinociception is a usual component of defensive reactions (Fanselow and Helmstetter, 1988) , and activation of this MeA-hypothalamus SP pathway could trigger defensive reactions after SP microinjections in the MeA. Turner et al. (1967) reported that lesions of the ventromedial region of the hypothalamus increased the reactivity to noxious stimuli. Other findings confirmed that this pathway is indeed controlled by NK-1 receptors (Shaikh et al., 1993; Han et al., 1996) . The present results also suggest that antinociception, in contrast to anxiogenic-like behavior, that is induced by SP in the MeA is mediated by NK-1 receptors because spantide blocked this effect. Additionally, the lack of effects of spantide per se in both the CeA and MeA suggests that NK-1 receptors modulate defense mechanisms only when they are recruited by the presence of aversive stimuli. Therefore, SP and NK-1 receptor activation may be phasically but not tonically involved in specific aspects of defensive behaviors (Carvalho et al., 2013; Ebner et al., 2004; Smith et al., 1999) . Many studies have shown that intra-dPAG microinjections of SP (or an NK-1 agonist) elicit long-lasting 22 kHz USVs in rats (Bassi et al., 2007a (Bassi et al., , 2007b De Araújo et al., 1999) . The playback of 22-kHz calls increases Fos labeling in the amygdala and PAG (Parsana et al., 2012; Sadananda et al., 2008) . Microinjection of SP or spantide in the BLA, CeA, and MeA did not produce any USVs, even when SP elicited anxiety-like behavior. These data led us to the following hypotheses. First, bilateral inactivation of the amygdala decreases shock-conditioned vocalizations (Borszcz and Leaton, 2003; Lee et al., 2001) , and USV emissions via stimulation of the amygdala can only be produced after the conditioning of stimuli (e.g., light and shock). Second, unconditioned USVs can only be produced in brain structures that are located in the lower levels of the neuroaxis because stimulation of the dPAG and anterior hypothalamus produces USVs (Bassi et al., 2007b (Bassi et al., , 2009 Brudzynski and Barnabi, 1996) . In our opinion, the amygdala serves as a feedback structure that regulates acoustic components of the modulation of the actual emotion, such as intensity and frequency. Another hypothesis involves the stimulation of higher brain structures (e.g., the prefrontal cortex) by the amygdala (Bourgeais et al., 2001 ), serving to maintain but not produce defensive behaviors (e.g., USVs) as long as information related to the aversive stimuli arrives in the amygdala. The production of USVs via SP/NK-1 mechanisms involves dPAG activation (Bassi et al., 2007a (Bassi et al., , 2007b .
In summary, the present study found that NK-1 receptor activation modulated specific phenotypes of defensive behavior in different nuclei of the amygdala where SP was injected. Substance P-related mechanisms in the BLA are not involved in the production of aversive states, analgesia, or USVs. The behavioral changes that were induced by SP were observed only when it was microinjected in the CeA and MeA. However, the aversive effects were associated with NK-1 receptor activation only in the CeA and not MeA. Additionally, SP produced antinociceptive effects only when it was microinjected in the MeA, an effect that was blocked by spantide. No USVs were emitted after the SP treatments. These data associate NK-1 mechanisms in the CeA and MeA with the processing of proximal aversive stimuli and corroborate and extend the involvement of the neurokininergic system in the modulation of defensive behaviors. The present study also extends earlier analyses of the involvement of NK-1 mechanisms in the output of defensive reactions instead of the processing of aversive information (Bassi et al., 2009; Brenes et al., 2012) . This could explain the efficacy of intra-MeA and intra-CeA spantide administration in attenuating defensive behaviors in the elevated plus maze and aversion-induced antinociception similarly to spantide administration in the dPAG and the lack of effects of microinjections in the BLA. Alternatively, NK-1 receptor activation in the MeA may be phasically involved in very specific aspects of fear and defensive behavior that are manifest only when the aversive stimulus is present, such as the height and open spaces associated with the elevated plus maze and thermal nociception in the tail-flick test. The present study was conducted as part of a series of experiments in male rats that are being performed in our laboratory to elucidate the roles of transmitters and neuromodulators in brain regions associated with the aversion system in rats and defensive behavior. One unresolved issue is whether and how this work is relevant clinically because the neurobiology of neurokinins is different between humans and rats. Additionally, the intracranial manipulations that were performed in the present study are not necessarily directly translatable to systemic administration that is used therapeutically. The extent to which the present findings are useful in the search for new therapeutic strategies is unclear. To date, sparse controlled clinical data on anxiety disorders have been reported. The NK-1 receptor antagonist GR205171 reduced symptoms of social anxiety and suppressed brain responses in the Trier Social Stress Test (Furmark et al., 2005) but was not effective in treating patients with posttraumatic stress disorder (Mathew et al., 2011) . A recent clinical trial reported the lack of efficacy of the NK-1 antagonist L-759274 as a treatment for generalized anxiety disorder (Michelson et al., 2012) . The present results may provide a better understanding of the neurochemical mediation of fear-related states. The involvement of other NK receptors, such as NK-3, in the SP-induced modulation of defensive behavior in the MeA and other brain structures deserves further investigation.
